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Background: Human T lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP)
is a chronic myelopathy characterized by motor dysfunction of the lower extremities and urinary disturbance.
Immunomodulatory treatments are the main strategy for HAM/TSP, but several issues are associated with long-term
treatment. We conducted a clinical trial with prosultiamine (which has apoptotic activity against HTLV-I-infected cells)
as a novel therapy in HAM/TSP patients.
Methods: We enrolled 24 HAM/TSP patients in this open-label clinical trial. Prosultiamine (300 mg, orally) was
administered once daily for 12 weeks. We monitored changes in the motor function of the lower extremities and urinary
function as well as copy numbers of the HTLV-I provirus in peripheral blood mononuclear cells (PBMCs).
Results: Improvement in the motor function of the lower extremities based on a reduction in spasticity (for example,
decrease in time required for walking and descending a flight of stairs) was observed. In an urodynamic study (UDS),
bladder capacity and detrusor pressure and then maximum flow rate increased significantly. Detrusor overactivity and
detrusor-sphincter dyssynergia improved in 68.8% and 45.5% of patients observed at pretreatment, respectively.
Improvement in UDS corresponded with improvements in the score of nocturia-quality of life questionnaire. HTLV-I
proviral copy numbers in PBMCs decreased significantly (approximately 15.4%) compared with pretreatment levels.
Conclusions: These data suggest that prosultiamine can safely improve motor dysfunction of the lower extremities and
urinary disturbance as well as reduce HTLV-I provirus levels in peripheral blood. It therefore has potential as a new
therapeutic tool for HAM/TSP patients.
Trial registration: University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) number,
UMIN000005969.
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Human T lymphotropic virus type I (HTLV-I) infects
approximately 10 to 20 million people worldwide, mainly
in large endemic areas such as southern Japan, the
Caribbean, Central and South America, the Middle East,
Melanesia, and equatorial regions of Africa [1,2]. HTLV-I is
a human retrovirus and the causative agent of adult Tcell
leukemia and HTLV-I-associated myelopathy/tropical
spastic paraparesis (HAM/TSP) [3,4]. HAM/TSP is a
chronic progressive myelopathy characterized by bilateral
pyramidal tracts involved with sphincteric disturbances [5].
Only a small proportion of HTLV-I-infected individuals
develop HAM/TSP. However, the main neurological
symptoms (for example, motor dysfunction of the
lower extremities accompanied by urinary disturbance)
are progressive and lead to a deterioration in the quality of
life (QoL) of patients once the myelopathy develops.
Therefore, novel and safe therapeutic regimens are needed
for HAM/TSP patients to use as treatment, or to prevent
disease progression.
The primary neuropathological feature of HAM/TSP
is chronic inflammation in the spinal cord caused by
high HTLV-I proviral load in peripheral blood. Immuno-
modulatory therapy such as corticosteroid hormones
and interferon (IFN)α has been the main treatment
administered to HAM/TSP patients to date [6]. Although
these treatments have produced good results in the short
term, their overall efficacy is controversial [6,7]. In addition,
it is not known if these treatments can be tolerated
as a long-term or lifelong treatment against HAM/TSP, or
whether they are necessary in the therapeutic strategy
against HAM/TSP. When treating HAM/TSP, the optimal
treatment is elimination of HTLV-I-infected cells from
peripheral blood because HTLV-I-infected CD4+ T cells




ide) is known as prosultiamine and as Alinamin®. It is a
product of Takeda Pharmaceutical Company Limited
(Osaka, Japan). Prosultiamine is a homolog of allithiamine,
which was originally synthesized from thiol-type vitamin
B1 and allicin [9]. For stability in the blood and efficient
access of vitamin B1 to tissues, prosultiamine was devel-
oped after allyl disulfide derived from allicin was substituted
with propyl disulfide in the structure of allithiamine [10].
Importantly, prosultiamine is pharmacologically stable and
is readily available for the treatment of Wernicke’s enceph-
alopathy and polyneuropathy induced by deficiency of vita-
min B1. Moreover, it has been shown to be safe for use in
Japan. Therefore, this drug could be utilized immediately
for conducting clinical trials in individuals with HAM/TSP.
Recently, we demonstrated that prosultiamine can
induce the caspase-dependent apoptosis of HTLV-I-infected cells through disruption of intracellular redox
reactions by a disulfide moiety in its structure [11].
Based on these data, we undertook a clinical trial based
on the intravenous administration of prosultiamine
in HAM/TSP patients with the purpose of targeting
HTLV-I-infected cells [11]. We found that prosul-
tiamine administration for 2 weeks was safe and
induced clinical improvement. Examples of such im-
provement included a decrease in (i) spasticity of the
lower extremities and (ii) levels of HTLV-I provirus in
peripheral blood mononuclear cells (PBMCs) to 30% to
50% of pretreatment levels.
As mentioned above, we do not know if prosultiamine
can be tolerated as a long-term treatment against
HAM/TSP or indeed if it is necessary in the therapeutic
strategy against HAM/TSP. Therefore, in the present
study, we administered prosultiamine via the oral route
for 12 weeks in subjects with HAM/TSP. We found that
such treatment could result in (i) improved motor func-
tion in the lower extremities based on a decrease in spas-
ticity, (ii) appreciable amelioration of associated urinary
disturbance, and (iii) a decrease in the level of HTLV-I pro-
virus in peripheral blood.
Methods
Ethical approval of the study protocol
This study protocol was approved by the clinical studies
review boards of Nagasaki University Hospital (Nagasaki,
Japan). The clinical trial was registered in the University
Hospital Medical Information Network Clinical Trials
Registry (UMIN-CTR) UMIN000005969. Written informed
consent was obtained from all patients enrolled in the study
for both participation in the study, and for inclusion of
personal data as shown in Table 1.
Patients
We enrolled 24 HAM/TSP patients (17 women and 7 men;
31 to 80 years (mean ± SD; 60.1 ± 11.2 years)) who fulfilled
criteria described previously [12]. The duration of illness
was 3 to 51 years (mean ± SD; 20.9 ± 12.1 years). Motor
function scores were rated from 0 to 13 according to the
motor disability score described by Osame et al. [13].
Concomitant therapies such as immunomodulators
and drugs for the neurogenic bladder were continued
on the condition that the dose was kept constant during the
study period. Intermittent self-catheterization with regard
to voiding was noted except in cases 7, 8, 10, 17, 21, 22, and
24. Patient profiles are shown in Tables 1 and 2.
Study design
Treatment protocol
Prosultiamine was imported from Ildon Pharmaceutical
Co., Ltd (Seoul, South Korea). Capsulated prosultiamine
(300 mg, orally) was administered once daily for 12 weeks.
Table 1 Profile of HAM/TSP patients enrolled and improvement of motor function in the lower extremities 12 weeks after treatment
Age (years) Sex Duration of
illuness (years)
Concomitant therapy Intermittent self-
catheterization
OMDSa Spasticity of the lower extremities
Case no. Immunomodulator Drug for neurogenic bladder







1 80 Female 23 No Yes Yes 6 6 Yes Yes
2 64 Female 16 No Yes Yes 6 6 Yes Yes
3 57 Male 51 PSL/ IFN-α Yes Yes 6 6 Yes Yes
4 51 Female 36 No Yes Yes 9 9 Yes Yes
5 67 Female 3 No Yes 3 3 No
6 61 Female 30 No Yes 5 5 Yes Yes
7 68 Female 12 No Yes No 4 4 Yes Yes
8 64 Male 11 PSL Yes No 5 5 Yes No
9 66 Male 23 PSL Yes Yes 9 9 Yes Yes
10 76 Male 23 No No 6 6 Yes Yes
11 53 Female 7 No Yes 6 6 Yes No
12 62 Female 12 PSL Yes Yes 4 4 No
13 44 Female 22 No Yes 6 6 Yes No
14 56 Male 10 No Yes Yes 5 5 Yes Yes
15 71 Female 45 No Yes Yes 9 9 No
16 78 Female 18 No Yes Yes 5 5 Yes Yes
17 50 Female 19 No No 5 5 Yes Yes
18 63 Female 29 No Yes Yes 8 8 Yes Yes
19 62 Female 9 PSL Yes Yes 8 8 Yes No
20 60 Female 34 No Yes Yes 2 1 No
21 46 Female 26 PSL Yes No 2 1 Yes Yes
22 31 Female 7 No Yes No 4 3 Yes Yes
23 56 Male 18 No Yes 10 10 No
24 56 Male 16 IFN-α No 2 2 Yes Yes
Remarks mean ± SD; mean ± SD; % improvement:
60.1 ± 11.2 20.9 ± 12.1 78.9 (P = 0.0003)c
aOsame’s motor function score (OMDS) was rated from 0 to 13 according to the disability grade [13].
bImprovement in spasticity of more than 1 grade according to the modifiedAshworth scale [14].
cStatistical significance was determined by the McNemar test.




















Table 2 Improvement of motor function in the lower extremities and urinary function 12 weeks after treatment





















1 26.5 21.6 18.5 N.E. No No No No
2 15.5 9.8 36.8 N.E. Yes No No No
3 11.5 10.5 8.7 8.6 7.7 10.5 Yes No Yes Yes
4 N.E. N.E. Yes No Yes Yes
5 5.3 4.9 7.5 3.8 3.7 2.6 No No Yes No
6 5.9 6.2 −5.1 4.1 4.2 −2.4 No No Yes No
7 8.9 9.5 −6.7 9.2 7.9 14.1 No No No No
8 12.6 13.3 −5.6 9.5 8.6 9.5 Yes No Yes Yes
9 N.E. N.E. Yes No No No
10 20 25.1 −25.5 N.E. No No No No
11 29.5 32.5 −10.2 N.E. Yes No Yes Yes
12 6.6 6.9 −4.5 4.4 4.3 2.3 Yes No Yes No
13 22.8 21.3 6.6 N.E. Yes No No No
14 15.4 11.3 26.6 14.3 11.4 20.3 No No No No
15 N.E. N.E. N.E. Yes No No No
16 13.7 20.9 −52.6 N.E. Yes Yes Yes Yes
17 13.3 11.5 13.5 10.0 7.3 27 Yes Yes No No
18 N.E. N.E. Yes Yes No No
19 N.E. N.E. Yes Yes Yes No
20 6.9 5.7 17.4 4.5 3.5 22.2 No No No No
21 5.7 4.1 28.1 3.6 3.5 2.8 Yes No No No
22 10.3 6.8 34 9.4 4.4 53.2 Yes Yes Yes Yes
23 N.E. N.E. No No Yes No
24 4.5 4.3 4.4 3.2 3.4 −6.3 Yes No No No
Remarks % improvement: % improvement:
68.8 (P = 0.0094)a 45.5 (P = 0.0736)a
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Neurological assessment
We monitored changes in neurological signs, motor
disability scores, time required for walking 10 m, and
time required for walking down a flight of stairs at 4-week
intervals. Spasticity of the lower extremities was graded
using the modified Ashworth scale (MAS) [14].
Urological assessment
Subjective symptoms were evaluated using the scores of
the Nocturia Quality of Life (N-QoL) questionnaire
[15-17] at 4-week intervals. The N-QoL questionnaire
comprised 13 items and dealt with daytime energy, worry,
productivity, sleep, and vitality. The total score ranged
from 0 (poorest QoL) to 100 (best QoL). The Duet® Logic
G2 system (Mediwatch UK Ltd., Rugby, UK) was used for
the urodynamic study (UDS). Bladder capacity, detrusor
pressure, maximum flow rate, detrusor overactivity (DO)
and detrusor-sphincter dyssynergia (DSD) were evaluated
by UDS.
Quantification of HTLV-I proviral load
For quantitative analyses of HTLV-I proviral loads, real-
time quantitative polymerase chain reaction (RT-qPCR) was
carried out in a Light-Cycler® FastStart DNA Master (Roche
Diagnostics, Mannheim, Germany) based on fluorescence
detection with SYBER® Green, as described previously [11].
Briefly, genomic DNA samples from PBMCs from HAM/
TSP patients were prepared using a Genomic DNA Extrac-
tion kit (Wako Pure Chemical Industries, Ltd., Osaka,
Japan) and were subjected to RT-PCR in a LightCycler PCR
system using Tax-specific primers, that is, forward primer
(5′- AAACAGCCCTGCAGATACAAAGT-3′) and reverse
primer (5′-ACTGTAGAGCTGAGCCGATAACG-3′),
as well as β-actin-specific primers, that is, forward primer
(5′-GCCCTCATTTCCCTCTCA-3′) and reverse primer
(5′-GCTCAGGCAGGAAAGACAC-3′). The PCR con-
dition for Tax was 40 cycles of denaturation (95°C, 15 s),
annealing (55°C, 5 s), extension (72°C, 10 s). That for
β-actin was 32 cycles of denaturation (95°C, 15 s),
annealing (62°C, 5 s), and extension (72°C, 15 s). The
HTLV-I proviral load per 10,000 cells was calculated
according to the following formula: (copy number of Tax)/
(copy number of β-actin/2) × 10,000
Statistical analyses
The Wilcoxon signed-rank test was used for statistical
analyses of the change of HTLV-I proviral copy numbers
and on the N-QoL scores or the urodynamic study
except for DO and DSD. The McNemar test was used
for statistical analyses of improvement of spasticity, DO
and DSD. JMP 10 (SAS Institute Inc., Cary, NC, USA)
was used as the software for statistical analyses. P< 0.05
was considered significant.Results
Improvement of motor function of the lower extremities
Improvement in Osame’s motor function score (OMDS)
was observed in three patients during treatment (Table 1).
After 12 weeks of treatment, improvement of more
than 1 grade of the degree of spasticity (evaluated according
to MAS) was observed in 15 of 19 patients in whom
spasticity of the lower extremities was observed before
treatment (% improvement; 78.9, P = 0.0003, McNemar
test) (Table 1). In time required for walking 10 m in 18
ambulatory patients, the decrease ranged from 4.4% to
36.8% was observed in 11 patients although the increase
ranged from 4.5% to 52.6% was observed in 7 patients
(Table 2). In time required for walking down a flight of
stairs in 12 patients, the decrease ranged from 2.3% to
53.2% was observed in 10 patients although the increase
of 2.4% or 6.3% was observed in 2 patients (Table 2).Improvement in urinary function
The conserved overall score of the N-QoL questionnaire
was significantly improved, with a significant improvement
of subscale scores at 12 weeks post treatment (Table 3). We
compared urinary function by UDS at pretreatment with
that at 12 weeks after treatment initiation. Bladder capacity
and detrusor pressure were significantly increased from
341.3 (SD 127.2) ml to 391.0 (SD 139.9) ml (P = 0.0097),
and 16.8 (SD 15.6) cm/H2O to 27.5 (SD 15.3) cm/H2O
(P = 0.0001), respectively, by this treatment (Figure 1a,b).
As analyzed in 18 patients whose own voiding function was
partially reserved, the maximum flow rate was increased
significantly from 7.5 (SD 6.2) ml/s to 10.2 (SD 5.6) ml/s
(P = 0.0139) (Figure 1c). Moreover, DO improved in
68.8% (11 of 16 patients observed at pretreatment) by
this treatment (P = 0.0094, McNemar test) (Table 2). DSD
also improved in 45.5% (5 of 11 patients observed at
pretreatment) 12 weeks after the start of treatment
(P = 0.0736, McNemar test) (Table 2).Decrease in HTLV-I proviral copy numbers in PBMCs
We monitored changes in copy numbers of the HTLV-I
provirus in PBMCs at pretreatment as well as 4, 8, and
12 weeks after treatment commencement (Figure 2a).
HTLV-I proviral copy numbers in 104 PBMCs decreased
gradually from 2,127 (SD 1,932) at pretreatment to 1,961
(SD 1,692) (P = 0.2776, vs pretreatment), 1,845 (SD 1,693)
(P = 0.0152, vs pretreatment) and 1,799 (SD 1,676)
(P = 0.0207, vs pretreatment) at 4, 8, and 12 weeks
after treatment, respectively. The level of HTLV-I
proviral copy numbers 12 weeks after treatment decreased
significantly (approximately 15.4%) from pretreatment
levels. Figure 2b shows the changes in HTLV-I proviral
copy numbers in each case between pretreatment and
12 weeks after treatment commencement. A decrease
Table 3 Changes in N-QoL scores after 12 weeks treatment with prosultiamine
Question Before treatment After treatment Pvalue
Q1 Concentration 0.6 ± 1.0 0.3 ± 1.6 0.1235
Q2 Low in energy 0.9 ± 1.1 0.4 ± 0.6 0.0077
Q3 Sleep during the day 1.5 ± 1.4 1.0 ± 1.1 0.0229
Q4 Productiveness 0.7 ± 0.9 0.3 ± 0.6 0.0830
Q5 Physical activities 1.0 ± 1.2 0.5 ± 0.8 0.0505
Q6 Fluid restriction 0.8 ± 1.2 0.7 ± 0.9 0.3270
Q7 Inadequate sleep at night 1.6 ± 1.5 0.7 ± 1.0 0.0070
Q8 Disturbance of others 0.8 ± 1.9 0.5 ± 1.8 0.0277
Q9 Preoccupation with waking at night 0.6 ± 1.1 0.3 ± 0.6 0.1235
Q10 Worry over condition worsening 1.5 ± 1.5 0.8 ± 1.1 0.0032
Q11 Worried over treatment options 1.5 ± 1.6 1.0 ± 1.3 0.0303
Q12 Overall bother 1.3 ± 1.3 0.8 ± 0.8 0.0238
Q13 Overall impact on everyday life 2.6 ± 2.8 0.9 ± 1.0 0.0023
Converted overall score (Q1 to 12) 73.2 ± 21.0 85.3 ± 19.9 0.0001
Subscale scores:
Sleep/Energy (Q1 to5, 7) 74.0 ± 20.7 87.0 ± 15.0 0.0001
Bother/Concern (Q6, Q8 to12) 72.4 ± 25.7 83.7 ± 21.2 0.0028
Subjective symptoms were evaluated using the scores of the Nocturia Quality of Life (N-QoL) questionnaire [15-17]. The score ranges of each question except Q13 are from
0 to 4. The score of Q13 is from 0 to 10. Converted overall score (0–100) = 100 × total converted scores (Q1 to 12)/4 × question numbers, converted score = 4-each raw




































































































Figure 1 Change in bladder function as evaluated by urodynamic study. Bladder capacity (a) and detrusor pressure (b) increased significantly
12 weeks after prosultiamine treatment. Maximum flow rate (c) increased significantly 12 weeks after prosultiamine treatment as assessed in 18
patients whose voiding function alone was partially reserved. Statistical significance was determined by the Wilcoxon signed-rank test.
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Figure 2 Change in human T lymphotropic virus type I (HTLV-I) proviral copy numbers in peripheral blood mononuclear cells (PBMCs). (a)
HTLV-I proviral copy numbers from 104 PBMCs decreased gradually until 12 weeks after prosultiamine treatment. The level of HTLV-I proviral copy numbers
12 weeks after prosultiamine treatment decreased by 15.4% compared with the time at pretreatment. (b) Changes in HTLV-I proviral copy numbers in
each case between pretreatment and 12 weeks after prosultiamine treatment. Statistical significance was determined by the Wilcoxon signed-rank test.
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numbers was observed in cased 8, 9, 11, 15 and 22.
Adverse effects
There were no serious adverse effects except mild
epigastric discomfort rated as ‘2’ evaluated according
to the Global Overall Symptom scale [18] in three
HAM/TSP patients. This symptom immediately resolved
after this clinical trial.
Discussion
Effective therapeutic regimens are needed urgently to treat
such myelopathic symptoms of HAM/TSP as spasticity of
lower extremities and urinary disturbance. To this end,
we administered prosultiamine via the oral route for 12
weeks in subjects with HAM/TSP. This treatment im-
proved (i) the motor ability of the lower extremities by de-
creasing spasticity, and (ii) urinary function. The mean
duration of illness of the patients enrolled in this study
was relatively long (approximately 21 years), so the effi-
cacy of this treatment is promising. Indeed, these data
suggest that the pathological processes in the spinal cord
of HAM/TSP patients are partially reversible and treatable
even if the tissues are damaged over a long period of time.The most striking effect in this clinical trial was
the amelioration of urinary disturbance in HAM/TSP
patients. The common urodynamic findings in HAM/TSP
patients are DO, DSD and detrusor hypoactivity [19].
However, as evaluated by UDS, prosultiamine treatment
resulted in a significant increase in detrusor pressure and
bladder capacity followed by an increase in maximum flow
rate with improved DO. DSD also improved in 45.5%
(5 of 11 patients observed at pretreatment) (P = 0.0736).
Although this value did not reach statistical significance, it
showed a tendency of improvement. This is the first time
that the therapeutic effect for urinary dysfunction in
HAM/TSP patients was evaluated in detail by UDS. With
respect to the effect of urinary conditions on the QoL of
HAM/TSP patients, nocturia, urgency, increased frequency
of urination and dysuria have been reported to be the main
problems [20]. Therefore, we evaluated the change in QoL
of patients using N-QoL questionnaires during treatment.
The improved UDS corresponded with improvements
in the score of N-QoL questionnaires. Concomitant
pharmacological therapies for the neurogenic bladder
were continued during the present study. However,
the efficacy of prosultiamine treatment, even in patients
who were not having concomitant therapies (cases 5, 6,
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improvement was dependent solely upon prosultiamine
treatment (Table 1). Overall, these data suggest that
prosultiamine treatment can reverse bladder dysfunction
in HAM/TSP patients.
Recently, two reports have focused on targeting HTLV-I
in therapeutic trials against HAM/TSP. One study used
reverse transcriptase (RT) inhibitors, whereas the other
used a histone deacetylase enzyme inhibitor for treatment
[21,22]. In the former, the results of combination therapy
(zidovudine + lamivudine) in a randomized, double-blind,
placebo-controlled study suggested that RT inhibitors
were not effective for targeting HTLV-I for the treatment
of HAM/TSP. In the latter study, long-term treatment
using valproic acid did not reduce the number of HTLV-I
-infected cells in peripheral blood [22]. A decrease in the
HTLV-I provirus in PBMCs was one of the primary
endpoints in our recent report [11]. Indeed, oral adminis-
tration of prosultiamine induced a significant decrease in
HTLV-I proviral copy numbers in PBMCs, However, the
rate of reduction was not as high as we had expected. This
finding might suggest a limitation of the protocol used in
the present study. Thus, the remarkable improvement of
motor dysfunction and urinary function in the present
study cannot be attributed solely to a decrease in HTLV-I
proviral copy numbers in PBMCs. The exact mechanism
is not known. Prosultiamine was originally developed for
efficient access of vitamin B1 to nervous tissues [10].
Although this drug is reduced to a part thiamine and
propyl disulfide by the intracellular reducing system after
penetration to the cells [10], it is suspected that the
disruption of intracellular redox system is induced during
reduction of disulfide bond leading to the apoptosis of
HTLV-I-infected cells [11]. Therefore, it might be conceiv-
able that, as one of the mechanisms, this drug functions
to induce the apoptosis of HTLV-I-infected cells in the
spinal cord even if the extent of reduction of the number
of HTLV-I-infected cells in PBMCs is relatively small.
Further investigations including analysis of cerebrospinal
fluid are needed to elucidate the exact mechanism of
action of prosultiamine.
Conclusions
In the present work we have demonstrated that oral
administration of prosultiamine can safely promote
improvement of motor function of the lower extremities
based on a reduction of spasticity along with appreciable
amelioration of urinary disturbance associated with a
decrease in the amount of HTLV-I provirus in peripheral
blood. Our results suggest that prosultiamine could
be a promising therapeutic tool for HAM/TSP patients.
Therefore, further studies are warranted, such as the
evaluation of prosultiamine treatment against HAM/TSP
in a large-scale, randomized, controlled study.Competing interests
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